psoriasis

Fenkel JM, Osborne JA, Armstrong AW, Strober B, Stein Gold L, Cameron M, Lebwohl M. Laboratory monitoring in patients with moderate to severe plaque psoriasis.[...]

By afschroeder • December 5, 2025

Matthews R, Armstrong AW, Augustin M, Baker C, Carrascosa JM, Kirby B, Langley R, McBride S, Reich A, Romiti R, Sampogna F, Warren RB. Is[...]

By afschroeder • November 23, 2025

Miao KL, Huang MY, Guo L, Lung K, Armstrong AW. Effect of biologic use on the development of psoriatic arthritis: A population-based study. J Eur[...]

By afschroeder • November 7, 2025

Engel P, Wu JJ. Updated Psoriasis Prevalence and Risk Factors in the United States-Insights From the 2023 NHIS. Exp Dermatol. 2025 Aug;34(8):e70146. doi: 10.1111/exd.70146. PMID:[...]

By afschroeder • August 7, 2025

Armstrong A, Strober B, Gisondi P, Orroth KK, Cordey M, Kent ST, Deignan C, Jardon S, Hernandez RK, Brookhart MA, Stein Gold L. Benefits of[...]

By afschroeder • August 7, 2025

Lebwohl MG, Koo JY, Armstrong AW, Strober BE, Yoon SH, Rawnsley NN, Goehring EL Jr, Jacobson AA. Brodalumab: Seven-Year US Pharmacovigilance Report. Dermatol Ther (Heidelb).[...]

By afschroeder • July 30, 2025

Strober B, Patel M, Kaldas MI, St John G, Photowala H, Sima AP, Eckmann T, Beeghly A, Armstrong A. Real-World Skin Clearance and Quality of[...]

By afschroeder • July 2, 2025

Armstrong AW, Feldman SR, Fitzgerald T, Alkousakis T, Sima A, Li A, Kang HJ, Main SI, Khattri S, Stein Gold L. Patient-Reported Outcomes by Baseline[...]

By afschroeder • June 12, 2025

Armstrong AW, Kircik L, Stein Gold L, Strober B, De Oliveira CHMC, Vaile J, Jou YM, Daamen C, Scharnitz T, Lebwohl M. Deucravacitinib: Laboratory Parameters[...]

By sjmartinez • March 22, 2025

Merola JF, Ferris LK, Sobell JM, Sofen H, Osborne J, Vaile J, Jou YM, Daamen C, Scotto J, Scharnitz T, Lebwohl M. Deucravacitinib: Adverse Events[...]

By sjmartinez • February 8, 2025